Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab plus intensive statin versus intensive statin for symptomatic intracranial atherosclerotic stenosis
ChiCTR2300078873Phase 4Recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of alirocumab and atorvastatin in cerebral arteriosclerosis, ischemic stroke and transient ischaemic attack (TIA) (2 arms), sponsored by Foshan First People's Hospital. Primary endpoint: Relative enhancement signal of the plaque at 6 months. Started Dec 2023; status: recruiting.
02
Drugs
alirocumabatorvastatin
03
Conditions
cerebral arteriosclerosisischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ChiCTR2300078873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078873.